This means that blocking CTLA-4 with Ipilimumab (anti-CTLA-4 monoclonal antibody, which has been accredited as checkpoint inhibitor for melanoma treatment) can significantly activate the molecular cascade, which may help enhance the immune response to tumor cells (14). This evidence concerns the gene CTLA4 and melanoma.